title: Glutamate transmission and addiction to cocaine.
abstract: A variety of data point to the possibility that neuroadaptations in glutamate transmission are produced by repeated exposure to cocaine that result in the expression of behaviors characteristic of addiction, such as craving and relapse. Using the reinstatement model of relapse in rats, glutamate release in the projection from the prefrontal cortex to the nucleus accumbens has been shown to underlie cocaine- and stress-primed reinstatement. In this report, four adaptations produced by withdrawal from repeated cocaine are described that may regulate the release of glutamate underlying reinstatement of drug-seeking resulted. (1) Neurons in the prefrontal cortex have increased levels of activator of G protein signaling 3 (AGS3) that causes reduced signaling through Gi coupled receptors, and normalization of AGS3 blocked cocaine-primed reinstatement. (2) The activity of the cystine-glutamate exchanger is reduced resulting in decreased extracellular glutamate in the nucleus accumbens, and normalization of exchanger activity prevented cocaine-primed reinstatement. (3) Metobotropic glutamate receptor function is diminished after repeated cocaine administration that results in reduced regulation of glutamate release. (4) Homer1 protein is reduced in the nucleus accumbens, and Homer2 knockout mice show enhanced responsiveness to cocaine. Taken together, there appears to be both pre- and postsynaptic changes in glutamate transmission that dysregulates the glutamatergic projection from the prefrontal cortex to the nucleus accumbens. These adaptations are hypothesized to facilitate glutamate release in response to a cocaine injection or acute stress and lead to the reinstatement of drug-seeking behavior.
authors.affiliation: Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, South Carolina 29464, USA. kalivasp@musc.edu
authors.forename: Peter W
authors.initials: PW
authors.lastname: Kalivas
authors.forename: Krista
authors.initials: K
authors.lastname: McFarland
authors.forename: Scott
authors.initials: S
authors.lastname: Bowers
authors.forename: Karer
authors.initials: K
authors.lastname: Szumlinski
authors.forename: Zheng-Xiong
authors.initials: ZX
authors.lastname: Xi
authors.forename: David
authors.initials: D
authors.lastname: Baker
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000502:physiology; D019970:Cocaine-Related Disorders / Q000503:physiopathology*; D005971:Glutamates / Q000502:physiology*; D020730:Guanine Nucleotide Dissociation Inhibitors; D000072233:Homer Scaffolding Proteins; D006801:Humans; D051379:Mice; D009479:Neuropeptides / Q000502:physiology; D051381:Rats; D018094:Receptors, Metabotropic Glutamate / Q000502:physiology; D012008:Recurrence; D015398:Signal Transduction / Q000502:physiology; D009435:Synaptic Transmission / Q000502:physiology*
chemical_list: D002352:Carrier Proteins; D005971:Glutamates; C498915:Gpsm1 protein, mouse; C498913:Gpsm1 protein, rat; D020730:Guanine Nucleotide Dissociation Inhibitors; C000606614:HOMER1 protein, human; D000072233:Homer Scaffolding Proteins; C000606623:Homer1 protein, mouse; C000606624:Homer1 protein, rat; C000606625:Homer2 protein, mouse; C000606626:Homer2 protein, rat; D009479:Neuropeptides; D018094:Receptors, Metabotropic Glutamate